Trial record 18 of 180 for:    "autosomal dominant partial epilepsy with auditory features" OR "Epilepsies, Partial"

EXTENT: EXtended Tolerability and Efficacy of a Novel Formulation of Oxcarbazepine in a Trial in Partial Epilepsy

This study has been terminated.
(Low recruitment rate)
Sponsor:
Collaborator:
FGK Clinical Research GmbH
Information provided by:
Desitin Arzneimittel GmbH
ClinicalTrials.gov Identifier:
NCT00391534
First received: October 23, 2006
Last updated: April 14, 2010
Last verified: January 2009
  Purpose

This study is intended to investigate the safety and efficacy of a novel formulation of oxcarbazepine that is released more slowly than the current formulation. The study medication will be used as a treatment against partial epilepsy.


Condition Intervention Phase
Partial Epilepsy
Drug: modified release formulation of oxcarbazepine (OXC MR)
Drug: immediate release formulation of oxcarbazepine (OXC IR)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Safety and Efficacy of a Novel Modified Release Formulation of Oxcarbazepine (OXC MR) vs an Immediate Release Oxcarbazepine (OXC IR) Product in Patients With Partial Epilepsy

Resource links provided by NLM:


Further study details as provided by Desitin Arzneimittel GmbH:

Primary Outcome Measures:
  • Maintenance dosage where dose up-titration has to be discontinued due to AEs [ Time Frame: whenever criterion is met ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Number of seizures during the trial [ Time Frame: Visit 1, Visit 2, Final Visit and each unscheduled visit ] [ Designated as safety issue: Yes ]
  • OXC and MHD plasma levels obtained from 6 patients per centre [ Time Frame: Visit 1, Visit 2, Final Visit and each unscheduled visit ] [ Designated as safety issue: No ]
  • Adverse event profile Plus (AEP) questionnaire-score [ Time Frame: at each patient contact ] [ Designated as safety issue: Yes ]
  • EpiTrack [ Time Frame: Visit 1, Visit 2, Final Visit and each unscheduled visit ] [ Designated as safety issue: Yes ]
  • Vital Signs and ECG [ Time Frame: Visit 1, Visit 2, Final Visit and each unscheduled visit ] [ Designated as safety issue: Yes ]
  • Laboratory parameters (hematology, serum chemistry, coagulation, urinalysis) [ Time Frame: Visit 1, Visit 2, Final Visit ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 100
Study Start Date: October 2006
Study Completion Date: November 2009
Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Oxcarbazepine MR
Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC MR. Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
Drug: modified release formulation of oxcarbazepine (OXC MR)
Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC MR. Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
Active Comparator: Oxcarbazepine IR
Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC IR (divided in two daily doses). Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
Drug: immediate release formulation of oxcarbazepine (OXC IR)
Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC IR (divided in two daily doses). Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.

Detailed Description:

This is a multi-centre, randomized, open-label, flexible-titration, controlled, parallel-group study to investigate the safety and efficacy of a novel modified release formulation of oxcarbazepine (OXC MR) compared to an immediate release oxcarbazepine (OXC IR) product in patients with partial epilepsy. Adult patients of both gender, aged at least 18 years with refractory partial epilepsy, with or without secondary generalisation receiving a stable background treatment with daily dosages of exactly 900 or 1200 or 1500 mg Oxcarbazepine will be enrolled. Concomitant medication consisting of maximal 2 additional AEDs (vagus nerve stimulator included) is allowed and must be kept stable throughout the study. Patients, who agree to participate, will first sign and date the informed consent and undergo an evaluation at screening visit to determine eligibility. Those patients who qualify will be enrolled in the study, assigned a patient ID, and will enter the 4-week baseline period. Each patient will receive a seizure diary to record the number of seizures during the baseline period. For Visit 1 the patient will return to the clinic and complete all baseline procedures. Patients who have met the entry criteria will be randomised. The two treatment groups consist of 50 patients each, one group to be treated with OXC MR b.i.d. and the other to be treated with OXC IR b.i.d. in a 1:1 randomization. Following assignment to one of both treatment groups the patient will enter the dose-titration phase. From Visit 1 (Study Day 1) a total daily dose of 1200 mg /1500 mg /1800 mg oxcarbazepine will be given to the randomised patients. From Day 6 the dosage will be titrated to a maximum total daily dose of 2700 mg in steps of 300 mg every 6th day. Patients who experienced intolerable adverse events could reduce their daily dose by 150 mg on the 2nd day of up-titration for the remainder of the treatment period. In case the reduced dosage will also not be tolerated, in a second step the dosage can be reduced by further 150 mg OXC. The maximal tolerated dose achieved on up-titration will be maintained up to the final visit (Study Day 26).

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Female and male patients with minimal age of 18 years on the date of the first study visit.
  • Stable treatment with Oxcarbazepine treatment (Timox® /Trileptal®), dosage: exactly 900 mg or exactly 1200 mg or exactly 1500 mg for at least 1 month prior to screening.
  • >= 2 partial onset seizures with or without secondary generalisation refractory to existing AED therapy within the baseline period.
  • Weight between >= 50 kg and < 100 kg.
  • for females with child-bearing potential: negative pregnancy rest and highly effective form of birth control (females using hormonal contraceptives should use a different or additional means of birth control, e.g. IUD, abstinence, vasectomized partner, double barriere methods with or without oral contraceptives)
  • Stable regimen of <= 2 concomitant AEDs (vagus nerve stimulator included) during the baseline period; lamotrigine dose may be adjusted at baseline.
  • Ethnic origin: Caucasian.
  • Subjects capable of complying with the study stipulations.
  • Patients who have provided written informed consent to participate in this study.

Exclusion Criteria:

  • Epilepsy secondary to progressive metabolic disease, malignant neoplasm, substance abuse, or active infection.
  • Status epilepticus at any time during the baseline period.
  • Lennox-Gastaut syndrome.
  • Generalized epilepsy as primary diagnosis.
  • Severe cardiac, pulmonary, haematological, hepatic, renal or neoplastic pathology.
  • Acute medical conditions and/or conditions that could interfere with the absorption, metabolism or excretion of oxcarbazepine.
  • History of clinically relevant psychiatric illness and/or drug abuse, drug addiction or alcoholism within the last 2 years.
  • Treatment with psychotropic drugs, anticholinergic drugs, anti-parkinson medication, α1-antagonists, α2-antagonists, carbamazepine, topiramate, felbamate, vigabatrin. Stable treatment with selective serotonin-reuptake-inhibitor (SSRI) having been given for at least 4 weeks prior to screening as supportive treatment of partial epilepsy can be accepted.
  • Intake of sodium lowering medication, e.g. diuretics and non-steroidal anti- inflammatory drugs. Occasional and short-term intake of non-steroidal anti- inflammatory drugs on demand (Ibuprofen, Paracetamol, ASS, Diclofenac and others) is allowed.
  • Hypersensitivity towards oxcarbazepine or chemically related drugs.
  • Low sodium serum levels (< 128 mmol/L). Sodium serum levels ≥ 126 and < 128 mmol/L can be accepted for inclusion, if these levels have been stable for at least 3 months.
  • Symptomatic hyponatremia.
  • Pregnancy or breast feeding.
  • Participation in drug trials during 3 months preceding the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00391534

Locations
Germany
Bergisch Gladbach, Germany
Bonn, Germany
Erlangen, Germany
Freiburg, Germany
Göttingen, Germany
Kehl-Kork, Germany
Sponsors and Collaborators
Desitin Arzneimittel GmbH
FGK Clinical Research GmbH
Investigators
Principal Investigator: Christian E. Elger, Prof. MD Klinik für Epileptologie, Universität Bonn, Bonn, Germany
Study Director: Martina Wangemann, Dr. Desitin Arzneimittel GmbH
  More Information

No publications provided

Responsible Party: Dr. Martina Wangemann, Desitin Arzneimittel GmbH
ClinicalTrials.gov Identifier: NCT00391534     History of Changes
Other Study ID Numbers: OXC-039/K, EudraCT No: 2006-003834-14
Study First Received: October 23, 2006
Last Updated: April 14, 2010
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Desitin Arzneimittel GmbH:
Epilepsy
oxcarbazepine

Additional relevant MeSH terms:
Epilepsies, Partial
Epilepsy
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Oxcarbazepine
Carbamazepine
Anticonvulsants
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cardiovascular Agents
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents

ClinicalTrials.gov processed this record on September 18, 2014